Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer

Recruiting now

Conditions studied: Pancreatic Ductal Adenocarcinoma

In brief

This study aims to develop and validate a predictive microRNA (miRNA) panel to assess the response to neoadjuvant chemotherapy (NACT) in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC).

Key facts

Study ID

NCT07226154

Run by

City of Hope Medical Center

People needed

200

Starts

2024-11-15

Expected to finish

2026-06-18

Last updated by the study team

2025-11-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).
• Underwent neoadjuvant chemotherapy (FOLFIRINOX or Gemcitabine/nab-paclitaxel).
• Availability of pre-treatment plasma samples.
• Underwent curative-intent resection (R0 or R1).

You may not qualify if…

• Inadequate plasma samples or poor RNA quality for exosomal miRNA analysis.
• Non-adenocarcinoma histology.
• Presence of synchronous or multiple primary malignancies.
• Receipt of chemotherapy regimens other than standard FOLFIRINOX or gemcitabine plus nab-paclitaxel (GEM-NABP).
• Presence of active inflammatory or autoimmune diseases.

Where it is running

• City of Hope Medical Center — Duarte, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.